Chris Garabedian

Chris served as President and Chief Executive Officer of Sarepta Therapeutics from January, 2011 to March, 2015.  In his tenure at Sarepta, he established Sarepta as a leader in Rare Disease and RNA Technology and successfully advanced their lead drug candidate for Duchenne muscular dystrophy through late-stage development and a potential pathway for Accelerated Approval.  Previously he was Vice President of Corporate Strategy for Celgene Corporation from July 2007. From November 2005 to June 2007, Chris served as an independent consultant to early stage biopharmaceutical companies.

From 1997 to 1998 and from 1999 to November 2005, he worked at Gilead Sciences, Inc., where he served in a number of global leadership roles, including as Vice President of Corporate Development, Vice President of Marketing, and Vice President of Medical Affairs. Chris also held various commercial roles at COR Therapeutics, Inc. from 1998 to 1999 and at Abbott Laboratories from 1994 to 1997. He started his biopharmaceutical career as a consultant with Migliara/Kaplan Associates from 1991 to 1994. Chris received his BS in marketing from the University of Maryland.